MedTrace Logo

Pro-omega-3, Reduction of Inflammation and Modulation of Prematurity

NCT03739463 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2018-11-20

No results posted yet for this study

Summary

The aim of the project is to decrease the inflammatory status of pregnant women with preterm premature rupture of membranes to delay the initiation of labour that would inevitably lead to premature delivery. The main objective is to measure the mean duration between the initiation of the treatment and delivery in the two groups treated either with MAG-DHA or with the placebo.

Conditions

  • PPROM

Interventions

DIETARY_SUPPLEMENT

MAG-DHA

375 MG of MAG-DHA per capsules, two capsules BID

DIETARY_SUPPLEMENT

Oleic acid

375 MG of sunflower oil (oleic acid) per capsules, two capsules BID

Sponsors & Collaborators

  • Laval University

    collaborator OTHER

  • Université de Sherbrooke

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
42 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-12-03
Primary Completion
2019-11-05
Completion
2020-05-15

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03739463 on ClinicalTrials.gov